NEW YORK (GenomeWeb News) – CombiMatrix today said that it has regained compliance with a Nasdaq listing requirement calling for at least $2.5 million in stockholders' equity.

The Director of Listing Qualifications informed the Irvine, Calif.-based firm of its compliance in a letter dated Aug. 20, saying that based on CombiMatrix's Form 10-Q for the second quarter, which indicated that it had stockholders' equity of $5.7 million, the Nasdaq staff determined that the company was in compliance and "the matter is now closed."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.